First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.

Abstract

OBJECTIVE To harness the frontline therapy in advanced penile squamous cell carcinoma (PSCC), for which chemotherapy exerts moderate activity but poor efficacy. Dacomitinib is an irreversible, pan-epidermal growth factor receptor (HER) inhibitor. PATIENTS AND METHODS In a phase 2 study (NCT01728233), patients received dacomitinib 45 mg/day, orally… (More)
DOI: 10.1111/bju.14013

Topics

3 Figures and Tables

Cite this paper

@article{Necchi2017FirstlineTW, title={First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.}, author={Andrea Necchi and Salvatore Lo Vullo and Federica Perrone and Daniele Raggi and Patrizia Giannatempo and Giuseppina Calareso and Nicola Nicolai and Luigi Piva and Davide Biasoni and Mario Achille Catanzaro and Tullio Torelli and Silvia Bonfiglioli Stagni and Elena Togliardi and Maurizio Colecchia and Adele Busico and Annunziata Gloghini and Adele M Testi and Luigi Mariani and Roberto Salvioni}, journal={BJU international}, year={2017} }